<DOC>
	<DOCNO>NCT00008151</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody gemtuzumab ozogamicin locate cancer cell either kill deliver cancer-killing substance without harm normal cell . Peripheral stem cell bone marrow transplantation may able replace immune cell destroy chemotherapy radiation therapy use kill cancer cell . PURPOSE : Phase II trial study effectiveness gemtuzumab ozogamicin combine fludarabine total-body irradiation follow donor peripheral stem cell bone marrow transplantation treat patient advance acute myeloid leukemia myelodysplastic syndrome .</brief_summary>
	<brief_title>Gemtuzumab Ozogamicin , Fludarabine , Total-body Irradiation Followed Peripheral Stem Cell Bone Marrow Transplantation Treating Patients With Advanced Acute Myeloid Leukemia Myelodysplastic Syndrome</brief_title>
	<detailed_description>OBJECTIVES : I . Determine response disease-free survival 1 year patient advance acute myeloid leukemia myelodysplastic syndrome treat gemtuzumab ozogamicin , fludarabine , total body irradiation follow allogeneic peripheral blood stem cell bone marrow transplantation cyclosporine mycophenolate mofetil . II . Determine leukemic blast clearance blood marrow patient treat regimen . III . Determine safety pharmacokinetics gemtuzumab ozogamicin part regimen patient . IV . Determine incidence donor stem cell engraftment patient . V. Determine incidence severity graft-versus-host disease patient treat regimen . VI . Determine whether donor lymphocyte infusion safely use patient mixed full donor chimerism eliminate persistent progressive disease . OUTLINE : Patients receive gemtuzumab ozogamicin IV 2 hour day -21 ( first 5 patient ) -14 ( subsequent patient ) -7 , fludarabine IV 2 hour day -4 -2 . Patients undergo total body irradiation follow infusion allogeneic peripheral blood stem cell bone marrow day 0 . Patients receive oral IV cyclosporine 2-3 time daily day -3 56 ( relate donor ) 100 ( unrelated donor ) oral IV mycophenolate mofetil twice daily day 0 27 ( relate donor ) 40 ( unrelated donor ) . Patients receive 2 dos intrathecal methotrexate prior transplant additional 4 dos transplant . Patients cerebral spinal fluid ( CSF ) positive malignant cell instead receive intrathecal cytarabine , methotrexate hydrocortisone prior transplant twice weekly CSF blast clear . Patients persistent recurrent disease transplant may receive 3 donor lymphocyte infusion graft-versus-host disease less grade II great 5 % donor CD3 cell . Patients follow 6 month annually thereafter . PROJECTED ACCRUAL : A total 20-40 patient accrue study within 1-2 year .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Gemtuzumab</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis recurrent refractory acute myeloid leukemia CD33 positive Greater 5 % morphologically identify blast marrow OR Diagnosis myelodysplastic syndrome CD33 positive Greater 5 % morphologically identify blast marrow ( refractory anemia excess blast ( RAEB ) RAEB transformation ) Must donor meet follow criterion : HLAA , B , C , DRB1 DQB1 identical mismatch 1 allelic crossreactive antigen Under 75 year age PATIENT CHARACTERISTICS : Age : Any age Performance status : Not specify Life expectancy : Not specify Hematopoietic : WBC great 30,000/mm3 ( leukophereses hydroxyurea allow ) Hepatic : Bilirubin great 2 time upper limit normal No synthetic dysfunction No severe cirrhosis Renal : Not specify Cardiovascular : No symptomatic coronary artery disease No cardiac failure require therapy Pulmonary : DLCO least 35 % OR Receiving supplementary continuous oxygen Other : No uncontrolled infection No disease would severely limit life expectancy Not pregnant nursing Fertile patient must use effective contraception 1 year study PRIOR CONCURRENT THERAPY : No posttransplant growth factor 1 month mycophenolate mofetil administration</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>recurrent childhood acute myeloid leukemia</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>refractory anemia excess blast</keyword>
	<keyword>refractory anemia excess blast transformation</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>childhood myelodysplastic syndrome</keyword>
</DOC>